BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seo JW, Son HH, Choi JH, Lee SK. A Case of p-ANCA-Positive Propylthiouracil-Induced Pyoderma Gangrenosum. Ann Dermatol. 2010;22:48-50. [PMID: 20548880 DOI: 10.5021/ad.2010.22.1.48] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Croia C, Dini V, Loggini B, Manni E, Romanelli M, Migliorini P. Evaluation of neutrophil extracellular trap deregulated formation in pyoderma gangrenosum. Exp Dermatol 2021;30:1340-4. [PMID: 34057268 DOI: 10.1111/exd.14397] [Reference Citation Analysis]
2 de Boysson H, Martin Silva N, de Moreuil C, Néel A, de Menthon M, Meyer O, Launay D, Pagnoux C, Guillevin L, Puéchal X, Bienvenu B, Aouba A; French Vasculitis Study Group, French Internal Medicine Society. Neutrophilic Dermatoses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A French Multicenter Study of 17 Cases and Literature Review. Medicine (Baltimore) 2016;95:e2957. [PMID: 26986103 DOI: 10.1097/MD.0000000000002957] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 4.8] [Reference Citation Analysis]
3 Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 2017;177:72-83. [PMID: 27864925 DOI: 10.1111/bjd.15193] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
4 Chen B, Yang X, Sun S, Guo W, Li X, Zhang L, Guo Z, Han J, Li N. Propylthiouracil-Induced Vasculitis With Alveolar Hemorrhage Confirmed by Clinical, Laboratory, Computed Tomography, and Bronchoscopy Findings: A Case Report and Literature Review. Iran Red Crescent Med J 2016;18:e23320. [PMID: 27257510 DOI: 10.5812/ircmj.23320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Miyata T, Yashiro M, Hayashi M, Kamata K, Katsuoka K. Bullous pyoderma gangrenosum of the bilateral dorsal hands. J Dermatol 2012;39:1006-9. [PMID: 23039059 DOI: 10.1111/j.1346-8138.2012.01672.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Coster A, Dargent J, de Visscher N, Levecque P, Roquet-gravy P. Pyoderma gangrenosum avec anticorps anti-cytoplasme des neutrophiles de type anti-protéinase 3 (PR3-ANCA) induits par le propylthiouracile. Annales de Dermatologie et de Vénéréologie 2017;144:368-73. [DOI: 10.1016/j.annder.2017.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wang JY, French LE, Shear NH, Amiri A, Alavi A. Drug-Induced Pyoderma Gangrenosum: A Review. Am J Clin Dermatol 2018;19:67-77. [PMID: 28624960 DOI: 10.1007/s40257-017-0308-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
8 Vallini V, Andreini R, Bonadio A. Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. The International Journal of Lower Extremity Wounds 2017;16:191-201. [DOI: 10.1177/1534734617710980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Morais P, Baudrier T, Mota A, Cunha AP, Alves M, Neves C, Capela J, Sá-couto P, Azevedo F. Antineutrophil cytoplasmic antibody (ANCA)-positive cutaneous leukocytoclastic vasculitis induced by propylthiouracil confirmed by positive patch test: a case report and review of the literature. Cutaneous and Ocular Toxicology 2010;30:147-53. [DOI: 10.3109/15569527.2010.533318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Dasanu CA, Bockorny B, Alexandrescu DT. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. J Oncol Pharm Pract 2015;21:471-3. [PMID: 24986794 DOI: 10.1177/1078155214541975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]